Combination of vesicular stomatitis virus matrix protein gene therapy with low-dose cisplatin improves therapeutic efficacy against murine melonoma

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1219-1225

  Luo, Shan ^a   Chen, Ping ^a   Luo, Zi Chao ^b   Zhang, Ping ^a   Sun, Ping ^a   Shi, Wei ^a   Li, Zhi yong ^b   Zhang, Xiao Long ^a   Wang, Li Qiang ^a,b   Chen, Xin ^a   Wei, Yu Quan ^a   Wen, Yan Jun ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CISPLATIN; LIPOSOME; MATRIX PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; C57BL 6 MOUSE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE THERAPY; GROWTH INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; LOW DRUG DOSE; LYMPHOCYTIC INFILTRATION; MELANOMA; MELANOMA B16; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OUTCOME ASSESSMENT; PLASMID; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; COMBINED MODALITY THERAPY; GENE THERAPY; HUMANS; MELANOMA, EXPERIMENTAL; MICE; NIH 3T3 CELLS; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 77953183559     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01507.x     Document Type: Article

References (39)

1. Arriagada R, Bergman B, Dunant A. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004, 350:351-60.
2. Olaussen KA, Dunant A, Fouret P. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006, 355:983-91.
3. Chirino YI, Hernández-Pando R, Pedraza-Chaverrí J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 2004, 4:20.
4. Li G, Tian L, Hou JM. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin Cancer Res 2005, 11:4217-24.
5. Zhang R, Tian L, Chen LJ. Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma. Gene Ther 2006, 13:1263-71.
6. Perrotta C, Bizzozero L, Falcone S. Nitric oxide boosts chemo-immunotherapy via inhibition of acid sphingomyelinase in a mouse model of melanoma. Cancer Res 2007, 67:7559-64.
7. Li Q, Wei YQ, Wen YJ. Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. Int J Cancer 2004, 112:143-9.
8. Gaddy DF, Lyles DS. Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J Virol 2007, 81:2792-804.
9. Balachandran S, Barber GN. Vesicular stomatitis virus (VSV) therapy of tumors. IUBMB Life 2000, 50:135-8.
10. Balachandran S, Porosnicu M, Barber GN. Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis. J Virol 2001, 75:3474-9.
11. Stojdl DF, Lichty BD, tenOever BR. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4:263-75.
12. Shinozaki K, Ebert O, Kournioti C, Tai YS, Woo SL. Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 2004, 9:368-76.
13. Ahmed M, Cramer SD, Lyles DS. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004, 330:34-49.
14. Ebert O, Harbaran S, Shinozaki K, Woo SL. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther 2005, 12:350-8.
15. Letchworth GJ, Rodriguez LL, Del cbarrera J. Vesicular stomatitis. Vet J 1999, 157:239-60.
16. Forger JM, Bronson RT, Huang AS, Reiss CS. Murine infection by vesicular stomatitis virus: initial characterization of the H-2d system. J Virol 1991, 65:4950-8.
17. Huneycutt BS, Bi Z, Aoki CJ, Reiss CS. Central neuropathogenesis of vesicular stomatitis virus infection of immunodeficient mice. J Virol 1993, 67:6698-706.
18. Sur JH, Allende R, Doster AR. Vesicular stomatitis virus infection and neuropathogenesis in the murine model are associated with apoptosis. Vet Pathol 2003, 40:512-20.
19. Kopecky SA, Lyles DS. The cell-rounding activity of the vesicular stomatitis virus matrix protein is due to the induction of cell death. J Virol 2003, 77:5524-8.
20. Kopecky SA, Lyles DS. Contrasting effects of matrix protein on apoptosis in HeLa and BHK cells infected with vesicular stomatitis virus are due to inhibition of host gene expression. J Virol 2003, 77:4658-69.
21. Gaddy DF, Lyles DS. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J Virol 2005, 79:4170-9.
22. Ahmed M, McKenzie MO, Puckett S, Hojnacki M, Poliquin L, Lyles DS. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 2003, 77:4646-57.
23. Zhong Q, Wen YJ, Yang HS. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol 2008, 19:1584-91.
24. Zhao JM, Wen YJ, Li Q. A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J 2008, 22:4272-80.
25. Du XB, Lang JY, Xu JR. Vesicular stomatitis virus matrix protein gene enhances the antitumor effects of radiation via induction of apoptosis. Apoptosis 2008, 13:1205-14.
26. Shi W, Tang Q, Chen X. Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med 2009, 87:493-506.
27. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997, 15:647-52.
28. Yang F, Li Z, Deng H. Efficient inhibition of ovarian cancer growth and prolonged survival by transfection with a novel pro-apoptotic gene, hPNAS-4, in a mouse model. In vivo and in vitro results. Oncology 2008, 75:137-44.
29. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL. Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci U S A 2000, 97:4802-7.
30. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc Ser A 1972, 135:185-207.
31. Malaguarnera L. Implications of apoptosis regulators in tumorigenesis. Cancer Metastasis Rev 2004, 23:367-87.
32. Ferreira CG, Epping M, Kruyt FA, Giaccone G. Apoptosis: target of cancer therapy. Clin Cancer Res 2002, 8:2024-34.
33. Zupi G, Scarsella M, Semple SC, Mottolese M, Natali PG, Leonetti C. Antitumor efficacy of bcl-2 and c-myc antisense oligonucleotides in combination with cisplatin in human melanoma xenografts: relevance of the administration sequence. Clin Cancer Res 2005, 11:1990-8.
34. Bourhis J, Rivera F, Mesia R. Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2006, 24:2866-72.
35. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res 2000, 60:5659-66.
36. Megyeri K, Orosz L, Kemény L. Vesicular stomatitis virus infection triggers apoptosis associated with decreased DeltaNp63alpha and increased Bax levels in the immortalized HaCaT keratinocyte cell line. Biomed Pharmacother 2007, 61:254-60.
37. Schirrmacher V, Haas C, Bonifer R, Ahlert T, Gerhards R, Ertel C. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther 1999, 6:63-73.
38. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001, 411:380-4.
39. Plautz GE, Yang ZY, Wu BY, Gao X, Huang L, Nabel GJ. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci U S A 1993, 90:4645-9.